> Hot share tips
> All the big AIM fraud exposés
> 300 articles and podcasts a month
> Original investigations by our experienced team
> No ads, no click-bait, no auto-play videos
By Tom Winnifrith | Sunday 8 February 2015
Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
A few weeks earlier than we had expected, Premaitha Health (NIPT) has announced that it has received CE-mark approval for its Iona test and will therefore launch it commercially at once. This is good news and the shares are now 23.5p – 24.5p.
The IONA® test uses next-generation sequencing technology to estimate the risk of a fetus having Down's syndrome (Trisomy 21), Edwards' syndrome (Trisomy 18) and Patau's syndrome (Trisomy 13) - it is more sensitive and specific than the current combined test, providing accurate and reliable screening results to pregnant women. And it means fewer invasive tests and thus fewer miscarriages.
The potential market is vast. The question is how quickly can Premaitha monitise this and my conversations suggest we could get news on that very soon which will spark a further re-rating of the share price.
House broker Panmure Gordon has upped its target from 23p to 28p and will undoubtedly up it again when the first sales are announced. We tipped this at a 15p offer, the target remains 30p to sell. There is still upside and we expect news on commercialisation very shortly to deliver this. At worst a strong hold
This article first appeared on the Nifty Fifty website run by Tom Winnifrith, Steve Moore and Lucian Miers - sorry paying customers come first. To read Lucian's next shorting idea next weekend and to catch the next value investment share tip from Tom & Steve out shortly click HERE
Never miss a story.
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |